Fortress Biotech (NASDAQ:FBIO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.42) by 28.57 percent. This is a 15.38 percent decrease over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $16.079 million which missed the analyst consensus estimate of $21.018 million by 23.50 percent. This is a 6.34 percent increase over sales of $15.120 million the same period last year.